IVIG is an experimental therapy for AD and therefore there is not information about stakeholders.

In Australia {National Blood Authority} {7}, the key stakeholders involved with the supply, prescribing, dispensing, administration and use of IVIG are:

• National Blood Authority which e.g. manage contracts with suppliers;
• Funding Governments which e.g. provide funding for supply of IVIG;
• National and local committees which e.g. provide advice on options to strengthen prescribing practices;
• Prescribers who prescriber IVIG treatments in accordance with the Criteria;
• Patients who e.g. understand treatment risks and benefits;
• Authoriser which e.g. authorize access to government funded product for eligible patients;
• Dispenser who e.g. plan and manage product ordering appropriate to clinical demand;
• Distributor who e.g. plan and manage inventory levels according to the standards and clinical demand;
• Nurse who e.g. ensure patient’s authorization and consent to IVIG treatment.